Breath Test for Diagnosing Fungal Pneumonia
This type of fungal pneumonia is difficult to diagnose and in most cases a lung biopsy is necessary to obtain more accurate identification. However, such an invasive procedure could be difficult, and even dangerous, for debilitated patients with weakened immune systems, including organ or bone marrow transplant recipients and patients on chemotherapy.
Hence, the challenge for experts is to find a noninvasive method that can also identify the type of fungus causing pneumonia to enable timely and targeted treatment in these cases. Sophia Koo, MD, of Brigham and Women's Hospital in Boston (MA, USA), and her colleagues set out to find a unique "chemical signature" in the breath of patients being evaluated for fungal pneumonia. They prospectively collected breath samples from patients with suspected invasive fungal pneumonia from 2011 to 2013.
In their research, Dr. Koo et al. identified several compounds, or metabolites, normally produced by Aspergillus fumigatus and other fungi that can cause pneumonia. The next step was to analyse breath samples from 64 patients with suspected cases of invasive aspergillosis. This would allow the team to assess if it was possible to distinguish patients with this fungal pneumonia from patients who did not have this illness.
New Technique Detects Fungal Infection with High Accuracy
Based on the identification of these fungal compounds in the breath samples, the researchers were able to identify patients with the fungal infection with high accuracy: 94 percent sensitivity and 93 percent specificity. This means that the "breath test" was able to detect 94 percent of patients who actually had or probably had the disease, and misidentified as infected seven percent of patients who did not have the infection.
According to the hospital team, the breath collection procedure was implemented without any problem. It was well-tolerated, including by patients who had difficulty breathing or required supplemental oxygen.
"Identification of the underlying microbial etiology remains elusive in most patients with pneumonia, even with invasive diagnostic measures," Dr. Koo noted. "Our findings provide proof-of-concept that we can harness detection of species-specific metabolites to identify the precise microbial cause of pneumonia, which may guide appropriate treatment of these infections."
More work is needed to validate the findings and refine the approach before it can be considered for clinical use, the researchers said. If supported by future research, the new technique also may be used in other types of pneumonia. "We can likely also use this volatile metabolite profiling approach to identify other, more common causes of pneumonia," Dr. Koo pointed out.
Image Credit: Wikimedia Commons
Published on : Fri, 24 Oct 2014
Print as PDF
medos customized tubing sets have been individually designed, so that all customer requirements, depending on application and need can be realized. Furthermore tubing sets can be refined by rheoparin or x.eed coating. Customized and standard tubing sets...
The HAMILTON-C1 neo is a versatile neonatal ventilator that combines invasive and noninvasive modes with the additional options of nCPAP and high flow oxygen therapy. The integrated turbine allows it to be operated independently of a compressed air supply....
The HAMILTON-T1 combines for the first time the functionality of a fully featured intensive care unit ventilator with the compactness and ruggedness required for transport. This is why the HAMILTON-T1 enables you to provide optimal ventilation therapy...
The technical and clinical reference standard for all B·R·A·H·M·S PCT assays. All clinical cut-offs and algorithms were developed based on B·R·A·H·M·S PCT sensitive KRYPTOR. Homogeneous immunoassay for the quantitative d
Get an complete overview of your POCT setup - from one dashboard Your point-of-care-testing setup probably involves many different types of devices from various manufacturers. Radiometer's AQURE point-of-care management system can give you an overview...